In summary, our findings suggested that AREG promoted cancer cell motility of osteosarcoma and up-regulated the expression of ICAM-1 through the EGFR/PI3K/Akt/NF-κB signaling pathway (Figure 7). Here, NFKB1 is linked to cancer.